Home > Dermatology > AAD 2022 > Atopic Dermatitis: Novel Agents Enter the Stage > Lebrikizumab treatment leads to encouraging outcomes in multiple traits of AD

Lebrikizumab treatment leads to encouraging outcomes in multiple traits of AD

Presented By
Prof. Jonathan Silverberg, George Washington University School of Medicine, USA
Conference
AAD 2022
Trial
Phase 3, ADvocate1; ADvocate2
Significant reductions in eczema, sleep loss, and itch were observed in patients treated with the IL-13 blocker lebrikizumab for atopic dermatitis (AD). These results of the phase 3 ADvocate1 and ADvocate2 trials were also reflected in a meaningful improvement of quality of life. IL-13 plays a key role in the multifactorial pathogenesis of AD [1,2]. It not only promotes inflammation but also negatively influences the function of the epidermal barrier. Lebrikizumab selectively targets soluble IL-13 resulting in the inhibition of IL-13 signalling [3]. The 2 randomised, double-blind, placebo-controlled, phase 3 trials ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967) assessed lebrikizumab as monotherapy for moderate-to-severe AD. Prof. Jonathan Silverberg (George Washington ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on